Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Primary Open Angle Glaucoma
Interventions: Canaloplasty using the iTrack microcatheter with Healon GV Pro, Canaloplasty using the Omni surgical system with Healon GV Pro, Canaloplasty using the iTrack microcatheter with Healon Pro, Canaloplasty using the Omni surgical system with Healon Pro; Device
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Glendale, Arizona • Beverly Hills, California • Orange, California + 4 more

Conditions: Obesity, Overweight
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 18 more

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C (treprostinil diolamine); Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Hypertension, Diabetes Mellitus, Maternal Health
Interventions: digital health delivered multicomponent intervention; Behavioral
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 22,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Uncontrolled Hypertension
Interventions: Class instruction of breathing exercises, DVD instruction of breathing exercises, Control; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Glaucoma, Ocular Hypertension
Interventions: OTX-TP, Timolol; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Type 2 Diabetes, Hypertension
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Venous Insufficiency
Interventions: Physical Conditioning; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: East Orange, New Jersey

Conditions: Autonomic Nervous System Disease, Healthy, Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension, Diabetes
Interventions: cocoa; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cognitive Decline, Blood Pressure, Hypertension
Interventions: Clinical Support Decision Tool; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 70 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Essential Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Xen Gel Stent; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: High Blood Pressure
Interventions: DASH Plus, DASH - C; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: CTX340, Placebo; Drug
Lead sponsor: CRISPR Therapeutics AG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Port Orange, Florida

Conditions: Open Angle Glaucoma
Interventions: NCX 470, Placebo; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 16 more

Conditions: Hypertension, Cardiovascular Diseases, Diabetes
Interventions: Herbiotics Oral + Ent Probiotic, Placebo; Dietary Supplement
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension, Cardiovascular Diseases, Arterial Hypertension
Interventions: Heat Therapy Group, Aerobic Exercise Group; Other
Lead sponsor: University of Oregon; Other
Eligibility: 35 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more

Conditions: Cardiovascular Diseases, Diabetes, Obesity, Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertension
Interventions: valsartan and amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Hypertension in Pregnancy, Obstetrical Complications
Interventions: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 14 Years to 56 Years · Female only
Enrollment: 4,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Glaucoma
Interventions: Virtual Reality Visual Field, Standard Automated Perimetry; Device · Diagnostic Test
Lead sponsor: University of Miami; Other
Eligibility: 1 Year to 90 Years
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Multicenter Ab-interno Glaucoma Study Investigating Canaloplasty

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Examining Digital Health Care Delivery Models Through Medicaid Collaborative

Pranayama Breathing and Uncontrolled Hypertension

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Physical Conditioning in Management of Chronic Venous Insufficiency

Study of Norepinephrine Levels and Sympathetic Nervous System Activity

Flavanol-Rich Cocoa and Cerebral Blood Flow

Preventing Cognitive Decline by Reducing BP Target Trial

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Retrospective Review of Xen Gel Stent Implantation With Open vs. Closed Conjunctiva Approach

Randomized Trial of Tailored Dietary Advice to Lower Blood Pressure

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Probiotic Effect on Dietary Nitrate to Plasma Nitrite Production ( OPEDNPN )

Heat Therapy Versus Exercise Training in Hypertension

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Diabetes and Heart Disease Risk in Blacks

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

Patient Performance on Virtual Reality Visual Field Devices as Compared to Standard of Care